Lycera

Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary, areas of research, including immune metabolism, cell signaling, and immune cell differentiation.

The Company has a leading position in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immuno-oncology. In January 2017, Lycera announced the initiation of a Phase 1/2A study designed to find the biologically active or maximum tolerated dose of LYC-55716. Once the recommended Phase 2 dose is determined, the study will be expanded to determine single agent safety and activity in patients with advanced solid tumors. In October 2017, Lycera announced that LYC-55716 was advancing to Phase 2A development. The Phase 2A expansion is expected to enroll approximately 75 patients in 6 tumor cohorts. In January of 2018, Lycera announced the initiation of a Phase 1B combination study combining LYC-55716 with pembrolizumab in patients with metastatic Non-Small Cell Lung Cancer (NSCLC).

Lycera has also developed, novel ATPase modulators, for the treatment of autoimmune disease. ATPase modulators have been shown to be beneficial in several widely-accepted models for autoimmune disease, as well as in human translational systems, acting through pathways directly involved in immune regulation.